Feng Yang, Dimitrov Dimiter S
NCI-Frederick, National Institutes of Health, Frederick, MD, USA.
Methods Mol Biol. 2009;525:499-508, xiii. doi: 10.1007/978-1-59745-554-1_26.
Monoclonal antibodies are increasingly used for treatment of various diseases, mostly cancer therapy and auto-immune diseases. New chimeric, humanized, or fully-human antibodies specific to novel or already validated targets are being developed in many academic labs as well as in commercial entities. A validation of antibodies in preclinical settings is an important component of the road from discovery to clinic. Preparing sufficient amount of high-quality antibodies for preclinical studies is a challenge in some cases. This article summarizes protocols used in research laboratories, and is based on our own experience in the establishment of stable clones of CHO cells to scaling-up of tissue cultures for production of antibodies in bioreactors.
单克隆抗体越来越多地用于治疗各种疾病，主要是癌症治疗和自身免疫性疾病。许多学术实验室以及商业机构都在研发针对新的或已得到验证的靶点的新型嵌合抗体、人源化抗体或全人源抗体。在临床前环境中对抗体进行验证是从发现到临床这一过程的重要组成部分。在某些情况下，为临床前研究制备足够数量的高质量抗体是一项挑战。本文总结了研究实验室中使用的方案，这些方案基于我们自己建立CHO细胞稳定克隆以及扩大组织培养规模以在生物反应器中生产抗体的经验。
